In recent years, doctors, scientists, and experts who consult with pharmaceutical companies and hedge funds have come under increasing scrutiny from the media and their fellow professionals. The truth is, it’s a case of caveat emptor—both for the experts and for the organizations hiring them.
Biotech or medical device companies that are trying to promote new products, for example, could undermine a medical expert’s perceived objectivity if financial ties are not clearly disclosed up front. Experts providing information to hedge funds must be particularly careful not to disclose non-public information about publicly traded companies and run afoul of insider trading restrictions.
To read the full, original article click on this link: How VCs Use Advice from Experts | Xconomy
Author: John Steuart
